Cover Image
市場調查報告書

學名藥:全球產業年鑑

Generics Global Industry Almanac 2017

出版商 MarketLine 商品編碼 353039
出版日期 內容資訊 英文 450 Pages
訂單完成後即時交付
價格
Back to Top
學名藥:全球產業年鑑 Generics Global Industry Almanac 2017
出版日期: 2017年02月28日 內容資訊: 英文 450 Pages
簡介

本報告提供全球無酒精飲品產業分析,提供您各國和各地市場規模,部門,市場預測等等,加上主要企業簡介,為您概述為以下內容。

摘要整理

  • 市場銷售額
  • 市場銷售額的預測
  • 市場交易數量
  • 市場交易數量的預測
  • 地區部門

簡介

  • 關於本報告
  • 主要讀者
  • 該報告的利用方法
  • 定義

全球GENERICS

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析

GENERICS:亞太地區

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析

GENERICS:歐洲

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析

GENERICS:法國

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:德國

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:澳洲

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:巴西

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:加拿大

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:中國

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:印度

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS :印尼

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:義大利

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:日本

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS :墨西哥

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:荷蘭

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:北美

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析

GENERICS:俄羅斯

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:斯堪地那維亞

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析

GENERICS:新加坡

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:南非

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:韓國

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:西班牙

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:土耳其

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:英國

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

GENERICS:美國

  • 市場概要
  • 市場資料
  • 市場區隔
  • 市場展望
  • 波特的五力分析
  • 宏觀經濟指標

企業簡介

  • 主要企業

附錄

  • 調查手法
  • MarketLine

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MLIG16090-01

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the global generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The market value is evaluated at ex-factory prices.

Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

All currency conversions were calculated at constant average annual 2015 exchange rates.

The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.

The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
  • Leading company profiles reveal details of key generics market players' global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to buy

  • What was the size of the global generics market by value in 2016?
  • What will be the size of the global generics market in 2021?
  • What factors are affecting the strength of competition in the global generics market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the global generics market?

Table of Contents

EXECUTIVE SUMMARY

  • Market value
  • Market value forecast
  • Market volume
  • Market volume forecast
  • Geography segmentation

Introduction

  • What is this report about?
  • Who is the target reader?
  • How to use this report
  • Definitions

Global Generics

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis

Generics in Asia-Pacific

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis

Generics in Europe

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis

Generics in France

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Germany

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Australia

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Brazil

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Canada

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in China

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in India

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Indonesia

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Italy

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Japan

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Mexico

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in The Netherlands

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in North America

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis

Generics in Russia

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Scandinavia

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis

Generics in Singapore

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in South Africa

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in South Korea

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Spain

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in Turkey

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in The United Kingdom

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Generics in The United States

  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators

Company Profiles

  • Leading companies

Appendix

  • Methodology
  • About MarketLine

List of Tables

  • Table 1: Global generics market value: $ billion, 2012-16
  • Table 2: Global generics market volume: % of total pharma volume, 2012-16
  • Table 3: Global generics market geography segmentation: $ billion, 2016
  • Table 4: Global generics market value forecast: $ billion, 2016-21
  • Table 5: Global generics market volume forecast: % of total pharma volume, 2016-21
  • Table 6: Asia-Pacific generics market value: $ billion, 2012-16
  • Table 7: Asia-Pacific generics market volume: % of total pharma volume, 2012-16
  • Table 8: Asia-Pacific generics market geography segmentation: $ billion, 2016
  • Table 9: Asia-Pacific generics market value forecast: $ billion, 2016-21
  • Table 10: Asia-Pacific generics market volume forecast: % of total pharma volume, 2016-21
  • Table 11: Europe generics market value: $ billion, 2012-16
  • Table 12: Europe generics market volume: % of total pharma volume, 2012-16
  • Table 13: Europe generics market geography segmentation: $ billion, 2016
  • Table 14: Europe generics market value forecast: $ billion, 2016-21
  • Table 15: Europe generics market volume forecast: % of total pharma volume, 2016-21
  • Table 16: France generics market value: $ billion, 2012-16
  • Table 17: France generics market volume: % of total pharma volume, 2012-16
  • Table 18: France generics market geography segmentation: $ billion, 2016
  • Table 19: France generics market value forecast: $ billion, 2016-21
  • Table 20: France generics market volume forecast: % of total pharma volume, 2016-21
  • Table 21: France size of population (million), 2012-16
  • Table 22: France gdp (constant 2005 prices, $ billion), 2012-16
  • Table 23: France gdp (current prices, $ billion), 2012-16
  • Table 24: France inflation, 2012-16
  • Table 25: France consumer price index (absolute), 2012-16
  • Table 26: France exchange rate, 2012-16
  • Table 27: Germany generics market value: $ billion, 2012-16
  • Table 28: Germany generics market volume: % of total pharma volume, 2012-16
  • Table 29: Germany generics market geography segmentation: $ billion, 2016
  • Table 30: Germany generics market value forecast: $ billion, 2016-21
  • Table 31: Germany generics market volume forecast: % of total pharma volume, 2016-21
  • Table 32: Germany size of population (million), 2012-16
  • Table 33: Germany gdp (constant 2005 prices, $ billion), 2012-16
  • Table 34: Germany gdp (current prices, $ billion), 2012-16
  • Table 35: Germany inflation, 2012-16
  • Table 36: Germany consumer price index (absolute), 2012-16
  • Table 37: Germany exchange rate, 2012-16
  • Table 38: Australia generics market value: $ billion, 2012-16
  • Table 39: Australia generics market volume: % of total pharma volume, 2012-16
  • Table 40: Australia generics market geography segmentation: $ billion, 2016
  • Table 41: Australia generics market value forecast: $ billion, 2016-21
  • Table 42: Australia generics market volume forecast: % of total pharma volume, 2016-21
  • Table 43: Australia size of population (million), 2012-16
  • Table 44: Australia gdp (constant 2005 prices, $ billion), 2012-16
  • Table 45: Australia gdp (current prices, $ billion), 2012-16
  • Table 46: Australia inflation, 2012-16
  • Table 47: Australia consumer price index (absolute), 2012-16
  • Table 48: Australia exchange rate, 2012-16
  • Table 49: Brazil generics market value: $ billion, 2012-16
  • Table 50: Brazil generics market volume: % of total pharma volume, 2012-16
  • Table 51: Brazil generics market geography segmentation: $ billion, 2016
  • Table 52: Brazil generics market value forecast: $ billion, 2016-21
  • Table 53: Brazil generics market volume forecast: % of total pharma volume, 2016-21
  • Table 54: Brazil size of population (million), 2012-16
  • Table 55: Brazil gdp (constant 2005 prices, $ billion), 2012-16
  • Table 56: Brazil gdp (current prices, $ billion), 2012-16
  • Table 57: Brazil inflation, 2012-16
  • Table 58: Brazil consumer price index (absolute), 2012-16
  • Table 59: Brazil exchange rate, 2012-16
  • Table 60: Canada generics market value: $ billion, 2012-16
  • Table 61: Canada generics market volume: % of total pharma volume, 2012-16
  • Table 62: Canada generics market geography segmentation: $ billion, 2016
  • Table 63: Canada generics market value forecast: $ billion, 2016-21
  • Table 64: Canada generics market volume forecast: % of total pharma volume, 2016-21
  • Table 65: Canada size of population (million), 2012-16
  • Table 66: Canada gdp (constant 2005 prices, $ billion), 2012-16
  • Table 67: Canada gdp (current prices, $ billion), 2012-16
  • Table 68: Canada inflation, 2012-16
  • Table 69: Canada consumer price index (absolute), 2012-16
  • Table 70: Canada exchange rate, 2012-16
  • Table 71: China generics market value: $ billion, 2012-16
  • Table 72: China generics market volume: % of total pharma volume, 2012-16
  • Table 73: China generics market geography segmentation: $ billion, 2016
  • Table 74: China generics market value forecast: $ billion, 2016-21
  • Table 75: China generics market volume forecast: % of total pharma volume, 2016-21
  • Table 76: China size of population (million), 2012-16
  • Table 77: China gdp (constant 2005 prices, $ billion), 2012-16
  • Table 78: China gdp (current prices, $ billion), 2012-16
  • Table 79: China inflation, 2012-16
  • Table 80: China consumer price index (absolute), 2012-16
  • Table 81: China exchange rate, 2012-16
  • Table 82: India generics market value: $ billion, 2012-16
  • Table 83: India generics market volume: % of total pharma volume, 2012-16
  • Table 84: India generics market geography segmentation: $ billion, 2016
  • Table 85: India generics market value forecast: $ billion, 2016-21
  • Table 86: India generics market volume forecast: % of total pharma volume, 2016-21
  • Table 87: India size of population (million), 2012-16
  • Table 88: India gdp (constant 2005 prices, $ billion), 2012-16
  • Table 89: India gdp (current prices, $ billion), 2012-16
  • Table 90: India inflation, 2012-16
  • Table 91: India consumer price index (absolute), 2012-16
  • Table 92: India exchange rate, 2012-16
  • Table 93: Indonesia generics market value: $ billion, 2012-16
  • Table 94: Indonesia generics market volume: % of total pharma volume, 2012-16
  • Table 95: Indonesia generics market geography segmentation: $ billion, 2016
  • Table 96: Indonesia generics market value forecast: $ billion, 2016-21
  • Table 97: Indonesia generics market volume forecast: % of total pharma volume, 2016-21
  • Table 98: Indonesia size of population (million), 2012-16
  • Table 99: Indonesia gdp (constant 2005 prices, $ billion), 2012-16
  • Table 100: Indonesia gdp (current prices, $ billion), 2012-16
  • Table 101: Indonesia inflation, 2012-16
  • Table 102: Indonesia consumer price index (absolute), 2012-16
  • Table 103: Indonesia exchange rate, 2012-16
  • Table 104: Italy generics market value: $ billion, 2012-16
  • Table 105: Italy generics market volume: % of total pharma volume, 2012-16
  • Table 106: Italy generics market geography segmentation: $ billion, 2016
  • Table 107: Italy generics market value forecast: $ billion, 2016-21
  • Table 108: Italy generics market volume forecast: % of total pharma volume, 2016-21
  • Table 109: Italy size of population (million), 2012-16
  • Table 110: Italy gdp (constant 2005 prices, $ billion), 2012-16
  • Table 111: Italy gdp (current prices, $ billion), 2012-16
  • Table 112: Italy inflation, 2012-16
  • Table 113: Italy consumer price index (absolute), 2012-16
  • Table 114: Italy exchange rate, 2012-16
  • Table 115: Japan generics market value: $ billion, 2012-16
  • Table 116: Japan generics market volume: % of total pharma volume, 2012-16
  • Table 117: Japan generics market geography segmentation: $ billion, 2016
  • Table 118: Japan generics market value forecast: $ billion, 2016-21
  • Table 119: Japan generics market volume forecast: % of total pharma volume, 2016-21
  • Table 120: Japan size of population (million), 2012-16
  • Table 121: Japan gdp (constant 2005 prices, $ billion), 2012-16
  • Table 122: Japan gdp (current prices, $ billion), 2012-16
  • Table 123: Japan inflation, 2012-16
  • Table 124: Japan consumer price index (absolute), 2012-16
  • Table 125: Japan exchange rate, 2012-16
  • Table 126: Mexico generics market value: $ billion, 2012-16
  • Table 127: Mexico generics market volume: % of total pharma volume, 2012-16
  • Table 128: Mexico generics market geography segmentation: $ billion, 2016
  • Table 129: Mexico generics market value forecast: $ billion, 2016-21
  • Table 130: Mexico generics market volume forecast: % of total pharma volume, 2016-21
  • Table 131: Mexico size of population (million), 2012-16
  • Table 132: Mexico gdp (constant 2005 prices, $ billion), 2012-16
  • Table 133: Mexico gdp (current prices, $ billion), 2012-16
  • Table 134: Mexico inflation, 2012-16
  • Table 135: Mexico consumer price index (absolute), 2012-16
  • Table 136: Mexico exchange rate, 2012-16
  • Table 137: Netherlands generics market value: $ billion, 2012-16
  • Table 138: Netherlands generics market volume: % of total pharma volume, 2012-16
  • Table 139: Netherlands generics market geography segmentation: $ billion, 2016
  • Table 140: Netherlands generics market value forecast: $ billion, 2016-21
  • Table 141: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
  • Table 142: Netherlands size of population (million), 2012-16
  • Table 143: Netherlands gdp (constant 2005 prices, $ billion), 2012-16
  • Table 144: Netherlands gdp (current prices, $ billion), 2012-16
  • Table 145: Netherlands inflation, 2012-16
  • Table 146: Netherlands consumer price index (absolute), 2012-16
  • Table 147: Netherlands exchange rate, 2012-16
  • Table 148: North America generics market value: $ billion, 2012-16
  • Table 149: North America generics market volume: % of total pharma volume, 2012-16
  • Table 150: North America generics market geography segmentation: $ billion, 2016
  • Table 151: North America generics market value forecast: $ billion, 2016-21
  • Table 152: North America generics market volume forecast: % of total pharma volume, 2016-21
  • Table 153: Russia generics market value: $ billion, 2012-16
  • Table 154: Russia generics market volume: % of total pharma volume, 2012-16
  • Table 155: Russia generics market geography segmentation: $ billion, 2016
  • Table 156: Russia generics market value forecast: $ billion, 2016-21
  • Table 157: Russia generics market volume forecast: % of total pharma volume, 2016-21
  • Table 158: Russia size of population (million), 2012-16
  • Table 159: Russia gdp (constant 2005 prices, $ billion), 2012-16
  • Table 160: Russia gdp (current prices, $ billion), 2012-16
  • Table 161: Russia inflation, 2012-16
  • Table 162: Russia consumer price index (absolute), 2012-16
  • Table 163: Russia exchange rate, 2012-16
  • Table 164: Scandinavia generics market value: $ billion, 2012-16
  • Table 165: Scandinavia generics market volume: % of total pharma volume, 2012-16
  • Table 166: Scandinavia generics market geography segmentation: $ billion, 2016
  • Table 167: Scandinavia generics market value forecast: $ billion, 2016-21
  • Table 168: Scandinavia generics market volume forecast: % of total pharma volume, 2016-21
  • Table 169: Singapore generics market value: $ billion, 2012-16
  • Table 170: Singapore generics market volume: % of total pharma volume, 2012-16
  • Table 171: Singapore generics market geography segmentation: $ billion, 2016
  • Table 172: Singapore generics market value forecast: $ billion, 2016-21
  • Table 173: Singapore generics market volume forecast: % of total pharma volume, 2016-21
  • Table 174: Singapore size of population (million), 2012-16
  • Table 175: Singapore gdp (constant 2005 prices, $ billion), 2012-16
  • Table 176: Singapore gdp (current prices, $ billion), 2012-16
  • Table 177: Singapore inflation, 2012-16
  • Table 178: Singapore consumer price index (absolute), 2012-16
  • Table 179: Singapore exchange rate, 2012-16
  • Table 180: South Africa generics market value: $ billion, 2012-16
  • Table 181: South Africa generics market volume: % of total pharma volume, 2012-16
  • Table 182: South Africa generics market geography segmentation: $ billion, 2016
  • Table 183: South Africa generics market value forecast: $ billion, 2016-21
  • Table 184: South Africa generics market volume forecast: % of total pharma volume, 2016-21
  • Table 185: South Africa size of population (million), 2012-16
  • Table 186: South Africa gdp (constant 2005 prices, $ billion), 2012-16
  • Table 187: South Africa gdp (current prices, $ billion), 2012-16
  • Table 188: South Africa inflation, 2012-16
  • Table 189: South Africa consumer price index (absolute), 2012-16
  • Table 190: South Africa exchange rate, 2012-16
  • Table 191: South Korea generics market value: $ billion, 2012-16
  • Table 192: South Korea generics market volume: % of total pharma volume, 2012-16
  • Table 193: South Korea generics market geography segmentation: $ billion, 2016
  • Table 194: South Korea generics market value forecast: $ billion, 2016-21
  • Table 195: South Korea generics market volume forecast: % of total pharma volume, 2016-21
  • Table 196: South Korea size of population (million), 2012-16
  • Table 197: South Korea gdp (constant 2005 prices, $ billion), 2012-16
  • Table 198: South Korea gdp (current prices, $ billion), 2012-16
  • Table 199: South Korea inflation, 2012-16
  • Table 200: South Korea consumer price index (absolute), 2012-16
  • Table 201: South Korea exchange rate, 2012-16
  • Table 202: Spain generics market value: $ billion, 2012-16
  • Table 203: Spain generics market volume: % of total pharma volume, 2012-16
  • Table 204: Spain generics market geography segmentation: $ billion, 2016
  • Table 205: Spain generics market value forecast: $ billion, 2016-21
  • Table 206: Spain generics market volume forecast: % of total pharma volume, 2016-21
  • Table 207: Spain size of population (million), 2012-16
  • Table 208: Spain gdp (constant 2005 prices, $ billion), 2012-16
  • Table 209: Spain gdp (current prices, $ billion), 2012-16
  • Table 210: Spain inflation, 2012-16
  • Table 211: Spain consumer price index (absolute), 2012-16
  • Table 212: Spain exchange rate, 2012-16
  • Table 213: Turkey generics market value: $ billion, 2012-16
  • Table 214: Turkey generics market volume: % of total pharma volume, 2012-16
  • Table 215: Turkey generics market geography segmentation: $ billion, 2016
  • Table 216: Turkey generics market value forecast: $ billion, 2016-21
  • Table 217: Turkey generics market volume forecast: % of total pharma volume, 2016-21
  • Table 218: Turkey size of population (million), 2012-16
  • Table 219: Turkey gdp (constant 2005 prices, $ billion), 2012-16
  • Table 220: Turkey gdp (current prices, $ billion), 2012-16
  • Table 221: Turkey inflation, 2012-16
  • Table 222: Turkey consumer price index (absolute), 2012-16
  • Table 223: Turkey exchange rate, 2012-16
  • Table 224: United Kingdom generics market value: $ billion, 2012-16
  • Table 225: United Kingdom generics market volume: % of total pharma volume, 2012-16
  • Table 226: United Kingdom generics market geography segmentation: $ billion, 2016
  • Table 227: United Kingdom generics market value forecast: $ billion, 2016-21
  • Table 228: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21
  • Table 229: United Kingdom size of population (million), 2012-16
  • Table 230: United Kingdom gdp (constant 2005 prices, $ billion), 2012-16
  • Table 231: United Kingdom gdp (current prices, $ billion), 2012-16
  • Table 232: United Kingdom inflation, 2012-16
  • Table 233: United Kingdom consumer price index (absolute), 2012-16
  • Table 234: United Kingdom exchange rate, 2012-16
  • Table 235: United States generics market value: $ billion, 2012-16
  • Table 236: United States generics market volume: % of total pharma volume, 2012-16
  • Table 237: United States generics market geography segmentation: $ billion, 2016
  • Table 238: United States generics market value forecast: $ billion, 2016-21
  • Table 239: United States generics market volume forecast: % of total pharma volume, 2016-21
  • Table 240: United States size of population (million), 2012-16
  • Table 241: United States gdp (constant 2005 prices, $ billion), 2012-16
  • Table 242: United States gdp (current prices, $ billion), 2012-16
  • Table 243: United States inflation, 2012-16
  • Table 244: United States consumer price index (absolute), 2012-16
  • Table 245: United States exchange rate, 2012-15
  • Table 246: Allergan plc: key facts
  • Table 247: Allergan plc: key financials ($)
  • Table 248: Allergan plc: key financial ratios
  • Table 249: Mylan Inc.: key facts
  • Table 250: Mylan Inc.: key financials ($)
  • Table 251: Mylan Inc.: key financial ratios
  • Table 252: Sandoz International GmbH: key facts
  • Table 253: Teva Pharmaceutical Industries Limited: key facts
  • Table 254: Teva Pharmaceutical Industries Limited: key financials ($)
  • Table 255: Teva Pharmaceutical Industries Limited: key financial ratios
  • Table 256: Sun Pharmaceutical Industries Ltd.: key facts
  • Table 257: Sun Pharmaceutical Industries Ltd.: key financials ($)
  • Table 258: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
  • Table 259: Sun Pharmaceutical Industries Ltd.: key financial ratios
  • Table 260: Sanofi SA: key facts
  • Table 261: Sanofi SA: key financials ($)
  • Table 262: Sanofi SA: key financials (€)
  • Table 263: Sanofi SA: key financial ratios
  • Table 264: Les Laboratoires Servier: key facts
  • Table 265: STADA Arzneimittel AG: key facts
  • Table 266: STADA Arzneimittel AG: key financials ($)
  • Table 267: STADA Arzneimittel AG: key financials (€)
  • Table 268: STADA Arzneimittel AG: key financial ratios
  • Table 269: Aspen Pharmacare Holdings Ltd: key facts
  • Table 270: Aspen Pharmacare Holdings Ltd: key financials ($)
  • Table 271: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
  • Table 272: Aspen Pharmacare Holdings Ltd: key financial ratios
  • Table 273: O Ache Laboratorios Farmaceuticos S.A.: key facts
  • Table 274: EMS Sigma Pharma: key facts
  • Table 275: Eurofarma Laboratorios S.A.: key facts
  • Table 276: Apotex, Inc.: key facts
  • Table 277: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
  • Table 278: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
  • Table 279: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
  • Table 280: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
  • Table 281: Aurobindo Pharma Limited: key facts
  • Table 282: Aurobindo Pharma Limited: key financials ($)
  • Table 283: Aurobindo Pharma Limited: key financials (Rs.)
  • Table 284: Aurobindo Pharma Limited: key financial ratios
  • Table 285: Cipla Limited: key facts
  • Table 286: Cipla Limited: key financials ($)
  • Table 287: Cipla Limited: key financials (Rs.)
  • Table 288: Cipla Limited: key financial ratios
  • Table 289: Lupin Limited: key facts
  • Table 290: Lupin Limited: key financials ($)
  • Table 291: Lupin Limited: key financials (Rs.)
  • Table 292: Lupin Limited: key financial ratios
  • Table 293: PT Kalbe Farma Tbk: key facts
  • Table 294: PT Kalbe Farma Tbk: key financials ($)
  • Table 295: PT Kalbe Farma Tbk: key financials (IDR)
  • Table 296: PT Kalbe Farma Tbk: key financial ratios
  • Table 297: PT Indofarma (Persero), Tbk: key facts
  • Table 298: PT Indofarma (Persero), Tbk: key financials ($)
  • Table 299: PT Indofarma (Persero), Tbk: key financials (IDR)
  • Table 300: PT Indofarma (Persero), Tbk: key financial ratios
  • Table 301: PT Sanbe Farma: key facts
  • Table 302: PT Soho Global Health: key facts
  • Table 303: Daiichi Sankyo Co., Ltd.: key facts
  • Table 304: Daiichi Sankyo Co., Ltd.: key financials ($)
  • Table 305: Daiichi Sankyo Co., Ltd.: key financials (¥)
  • Table 306: Daiichi Sankyo Co., Ltd.: key financial ratios
  • Table 307: Sawai Pharmaceutical Co., Ltd.: key facts
  • Table 308: Sawai Pharmaceutical Co., Ltd.: key financials ($)
  • Table 309: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
  • Table 310: Sawai Pharmaceutical Co., Ltd.: key financial ratios
  • Table 311: Abbott Laboratories: key facts
  • Table 312: Abbott Laboratories: key financials ($)
  • Table 313: Abbott Laboratories: key financial ratios
  • Table 314: Krka, d. d., Novo mesto: key facts
  • Table 315: Krka, d. d., Novo mesto: key financials ($)
  • Table 316: Krka, d. d., Novo mesto: key financials (€)
  • Table 317: Krka, d. d., Novo mesto: key financial ratios
  • Table 318: Adcock Ingram Holdings Limited: key facts
  • Table 319: Adcock Ingram Holdings Limited: key financials ($)
  • Table 320: Adcock Ingram Holdings Limited: key financials (ZAR)
  • Table 321: Adcock Ingram Holdings Limited: key financial ratios
  • Table 322: Yuhan Corporation: key facts
  • Table 323: Yuhan Corporation: key financials ($)
  • Table 324: Yuhan Corporation: key financials (KRW)
  • Table 325: Yuhan Corporation: key financial ratios
  • Table 326: Esteve Group: key facts
  • Table 327: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts
  • Table 328: DEVA Holding: key facts
  • Table 329: DEVA Holding: key financials ($)
  • Table 330: DEVA Holding: key financials (TL)
  • Table 331: DEVA Holding: key financial ratios
  • Table 332: Nobel Pharmaceuticals: key facts

List of Figures

  • Figure 1: Global generics market value: $ billion, 2012-16
  • Figure 2: Global generics market volume: % of total pharma volume, 2012-16
  • Figure 3: Global generics market geography segmentation: % share, by value, 2016
  • Figure 4: Global generics market value forecast: $ billion, 2016-21
  • Figure 5: Global generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 6: Forces driving competition in the global generics market, 2016
  • Figure 7: Drivers of buyer power in the global generics market, 2016
  • Figure 8: Drivers of supplier power in the global generics market, 2016
  • Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016
  • Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016
  • Figure 11: Drivers of degree of rivalry in the global generics market, 2016
  • Figure 12: Asia-Pacific generics market value: $ billion, 2012-16
  • Figure 13: Asia-Pacific generics market volume: % of total pharma volume, 2012-16
  • Figure 14: Asia-Pacific generics market geography segmentation: % share, by value, 2016
  • Figure 15: Asia-Pacific generics market value forecast: $ billion, 2016-21
  • Figure 16: Asia-Pacific generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2016
  • Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2016
  • Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2016
  • Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2016
  • Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2016
  • Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2016
  • Figure 23: Europe generics market value: $ billion, 2012-16
  • Figure 24: Europe generics market volume: % of total pharma volume, 2012-16
  • Figure 25: Europe generics market geography segmentation: % share, by value, 2016
  • Figure 26: Europe generics market value forecast: $ billion, 2016-21
  • Figure 27: Europe generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 28: Forces driving competition in the generics market in Europe, 2016
  • Figure 29: Drivers of buyer power in the generics market in Europe, 2016
  • Figure 30: Drivers of supplier power in the generics market in Europe, 2016
  • Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016
  • Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2016
  • Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2016
  • Figure 34: France generics market value: $ billion, 2012-16
  • Figure 35: France generics market volume: % of total pharma volume, 2012-16
  • Figure 36: France generics market geography segmentation: % share, by value, 2016
  • Figure 37: France generics market value forecast: $ billion, 2016-21
  • Figure 38: France generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 39: Forces driving competition in the generics market in France, 2016
  • Figure 40: Drivers of buyer power in the generics market in France, 2016
  • Figure 41: Drivers of supplier power in the generics market in France, 2016
  • Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2016
  • Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2016
  • Figure 44: Drivers of degree of rivalry in the generics market in France, 2016
  • Figure 45: Germany generics market value: $ billion, 2012-16
  • Figure 46: Germany generics market volume: % of total pharma volume, 2012-16
  • Figure 47: Germany generics market geography segmentation: % share, by value, 2016
  • Figure 48: Germany generics market value forecast: $ billion, 2016-21
  • Figure 49: Germany generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 50: Forces driving competition in the generics market in Germany, 2016
  • Figure 51: Drivers of buyer power in the generics market in Germany, 2016
  • Figure 52: Drivers of supplier power in the generics market in Germany, 2016
  • Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016
  • Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2016
  • Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2016
  • Figure 56: Australia generics market value: $ billion, 2012-16
  • Figure 57: Australia generics market volume: % of total pharma volume, 2012-16
  • Figure 58: Australia generics market geography segmentation: % share, by value, 2016
  • Figure 59: Australia generics market value forecast: $ billion, 2016-21
  • Figure 60: Australia generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 61: Forces driving competition in the generics market in Australia, 2016
  • Figure 62: Drivers of buyer power in the generics market in Australia, 2016
  • Figure 63: Drivers of supplier power in the generics market in Australia, 2016
  • Figure 64: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016
  • Figure 65: Factors influencing the threat of substitutes in the generics market in Australia, 2016
  • Figure 66: Drivers of degree of rivalry in the generics market in Australia, 2016
  • Figure 67: Brazil generics market value: $ billion, 2012-16
  • Figure 68: Brazil generics market volume: % of total pharma volume, 2012-16
  • Figure 69: Brazil generics market geography segmentation: % share, by value, 2016
  • Figure 70: Brazil generics market value forecast: $ billion, 2016-21
  • Figure 71: Brazil generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 72: Forces driving competition in the generics market in Brazil, 2016
  • Figure 73: Drivers of buyer power in the generics market in Brazil, 2016
  • Figure 74: Drivers of supplier power in the generics market in Brazil, 2016
  • Figure 75: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016
  • Figure 76: Factors influencing the threat of substitutes in the generics market in Brazil, 2016
  • Figure 77: Drivers of degree of rivalry in the generics market in Brazil, 2016
  • Figure 78: Canada generics market value: $ billion, 2012-16
  • Figure 79: Canada generics market volume: % of total pharma volume, 2012-16
  • Figure 80: Canada generics market geography segmentation: % share, by value, 2016
  • Figure 81: Canada generics market value forecast: $ billion, 2016-21
  • Figure 82: Canada generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 83: Forces driving competition in the generics market in Canada, 2016
  • Figure 84: Drivers of buyer power in the generics market in Canada, 2016
  • Figure 85: Drivers of supplier power in the generics market in Canada, 2016
  • Figure 86: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016
  • Figure 87: Factors influencing the threat of substitutes in the generics market in Canada, 2016
  • Figure 88: Drivers of degree of rivalry in the generics market in Canada, 2016
  • Figure 89: China generics market value: $ billion, 2012-16
  • Figure 90: China generics market volume: % of total pharma volume, 2012-16
  • Figure 91: China generics market geography segmentation: % share, by value, 2016
  • Figure 92: China generics market value forecast: $ billion, 2016-21
  • Figure 93: China generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 94: Forces driving competition in the generics market in China, 2016
  • Figure 95: Drivers of buyer power in the generics market in China, 2016
  • Figure 96: Drivers of supplier power in the generics market in China, 2016
  • Figure 97: Factors influencing the likelihood of new entrants in the generics market in China, 2016
  • Figure 98: Factors influencing the threat of substitutes in the generics market in China, 2016
  • Figure 99: Drivers of degree of rivalry in the generics market in China, 2016
  • Figure 100: India generics market value: $ billion, 2012-16
  • Figure 101: India generics market volume: % of total pharma volume, 2012-16
  • Figure 102: India generics market geography segmentation: % share, by value, 2016
  • Figure 103: India generics market value forecast: $ billion, 2016-21
  • Figure 104: India generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 105: Forces driving competition in the generics market in India, 2016
  • Figure 106: Drivers of buyer power in the generics market in India, 2016
  • Figure 107: Drivers of supplier power in the generics market in India, 2016
  • Figure 108: Factors influencing the likelihood of new entrants in the generics market in India, 2016
  • Figure 109: Factors influencing the threat of substitutes in the generics market in India, 2016
  • Figure 110: Drivers of degree of rivalry in the generics market in India, 2016
  • Figure 111: Indonesia generics market value: $ billion, 2012-16
  • Figure 112: Indonesia generics market volume: % of total pharma volume, 2012-16
  • Figure 113: Indonesia generics market geography segmentation: % share, by value, 2016
  • Figure 114: Indonesia generics market value forecast: $ billion, 2016-21
  • Figure 115: Indonesia generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 116: Forces driving competition in the generics market in Indonesia, 2016
  • Figure 117: Drivers of buyer power in the generics market in Indonesia, 2016
  • Figure 118: Drivers of supplier power in the generics market in Indonesia, 2016
  • Figure 119: Factors influencing the likelihood of new entrants in the generics market in Indonesia, 2016
  • Figure 120: Factors influencing the threat of substitutes in the generics market in Indonesia, 2016
  • Figure 121: Drivers of degree of rivalry in the generics market in Indonesia, 2016
  • Figure 122: Italy generics market value: $ billion, 2012-16
  • Figure 123: Italy generics market volume: % of total pharma volume, 2012-16
  • Figure 124: Italy generics market geography segmentation: % share, by value, 2016
  • Figure 125: Italy generics market value forecast: $ billion, 2016-21
  • Figure 126: Italy generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 127: Forces driving competition in the generics market in Italy, 2016
  • Figure 128: Drivers of buyer power in the generics market in Italy, 2016
  • Figure 129: Drivers of supplier power in the generics market in Italy, 2016
  • Figure 130: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016
  • Figure 131: Factors influencing the threat of substitutes in the generics market in Italy, 2016
  • Figure 132: Drivers of degree of rivalry in the generics market in Italy, 2016
  • Figure 133: Japan generics market value: $ billion, 2012-16
  • Figure 134: Japan generics market volume: % of total pharma volume, 2012-16
  • Figure 135: Japan generics market geography segmentation: % share, by value, 2016
  • Figure 136: Japan generics market value forecast: $ billion, 2016-21
  • Figure 137: Japan generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 138: Forces driving competition in the generics market in Japan, 2016
  • Figure 139: Drivers of buyer power in the generics market in Japan, 2016
  • Figure 140: Drivers of supplier power in the generics market in Japan, 2016
  • Figure 141: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016
  • Figure 142: Factors influencing the threat of substitutes in the generics market in Japan, 2016
  • Figure 143: Drivers of degree of rivalry in the generics market in Japan, 2016
  • Figure 144: Mexico generics market value: $ billion, 2012-16
  • Figure 145: Mexico generics market volume: % of total pharma volume, 2012-16
  • Figure 146: Mexico generics market geography segmentation: % share, by value, 2016
  • Figure 147: Mexico generics market value forecast: $ billion, 2016-21
  • Figure 148: Mexico generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 149: Forces driving competition in the generics market in Mexico, 2016
  • Figure 150: Drivers of buyer power in the generics market in Mexico, 2016
  • Figure 151: Drivers of supplier power in the generics market in Mexico, 2016
  • Figure 152: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016
  • Figure 153: Factors influencing the threat of substitutes in the generics market in Mexico, 2016
  • Figure 154: Drivers of degree of rivalry in the generics market in Mexico, 2016
  • Figure 155: Netherlands generics market value: $ billion, 2012-16
  • Figure 156: Netherlands generics market volume: % of total pharma volume, 2012-16
  • Figure 157: Netherlands generics market geography segmentation: % share, by value, 2016
  • Figure 158: Netherlands generics market value forecast: $ billion, 2016-21
  • Figure 159: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 160: Forces driving competition in the generics market in the Netherlands, 2016
  • Figure 161: Drivers of buyer power in the generics market in the Netherlands, 2016
  • Figure 162: Drivers of supplier power in the generics market in the Netherlands, 2016
  • Figure 163: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016
  • Figure 164: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016
  • Figure 165: Drivers of degree of rivalry in the generics market in the Netherlands, 2016
  • Figure 166: North America generics market value: $ billion, 2012-16
  • Figure 167: North America generics market volume: % of total pharma volume, 2012-16
  • Figure 168: North America generics market geography segmentation: % share, by value, 2016
  • Figure 169: North America generics market value forecast: $ billion, 2016-21
  • Figure 170: North America generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 171: Forces driving competition in the generics market in North America, 2016
  • Figure 172: Drivers of buyer power in the generics market in North America, 2016
  • Figure 173: Drivers of supplier power in the generics market in North America, 2016
  • Figure 174: Factors influencing the likelihood of new entrants in the generics market in North America, 2016
  • Figure 175: Factors influencing the threat of substitutes in the generics market in North America, 2016
  • Figure 176: Drivers of degree of rivalry in the generics market in North America, 2016
  • Figure 177: Russia generics market value: $ billion, 2012-16
  • Figure 178: Russia generics market volume: % of total pharma volume, 2012-16
  • Figure 179: Russia generics market geography segmentation: % share, by value, 2016
  • Figure 180: Russia generics market value forecast: $ billion, 2016-21
  • Figure 181: Russia generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 182: Forces driving competition in the generics market in Russia, 2016
  • Figure 183: Drivers of buyer power in the generics market in Russia, 2016
  • Figure 184: Drivers of supplier power in the generics market in Russia, 2016
  • Figure 185: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016
  • Figure 186: Factors influencing the threat of substitutes in the generics market in Russia, 2016
  • Figure 187: Drivers of degree of rivalry in the generics market in Russia, 2016
  • Figure 188: Scandinavia generics market value: $ billion, 2012-16
  • Figure 189: Scandinavia generics market volume: % of total pharma volume, 2012-16
  • Figure 190: Scandinavia generics market geography segmentation: % share, by value, 2016
  • Figure 191: Scandinavia generics market value forecast: $ billion, 2016-21
  • Figure 192: Scandinavia generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 193: Forces driving competition in the generics market in Scandinavia, 2016
  • Figure 194: Drivers of buyer power in the generics market in Scandinavia, 2016
  • Figure 195: Drivers of supplier power in the generics market in Scandinavia, 2016
  • Figure 196: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2016
  • Figure 197: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2016
  • Figure 198: Drivers of degree of rivalry in the generics market in Scandinavia, 2016
  • Figure 199: Singapore generics market value: $ billion, 2012-16
  • Figure 200: Singapore generics market volume: % of total pharma volume, 2012-16
  • Figure 201: Singapore generics market geography segmentation: % share, by value, 2016
  • Figure 202: Singapore generics market value forecast: $ billion, 2016-21
  • Figure 203: Singapore generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 204: Forces driving competition in the generics market in Singapore, 2016
  • Figure 205: Drivers of buyer power in the generics market in Singapore, 2016
  • Figure 206: Drivers of supplier power in the generics market in Singapore, 2016
  • Figure 207: Factors influencing the likelihood of new entrants in the generics market in Singapore, 2016
  • Figure 208: Factors influencing the threat of substitutes in the generics market in Singapore, 2016
  • Figure 209: Drivers of degree of rivalry in the generics market in Singapore, 2016
  • Figure 210: South Africa generics market value: $ billion, 2012-16
  • Figure 211: South Africa generics market volume: % of total pharma volume, 2012-16
  • Figure 212: South Africa generics market geography segmentation: % share, by value, 2016
  • Figure 213: South Africa generics market value forecast: $ billion, 2016-21
  • Figure 214: South Africa generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 215: Forces driving competition in the generics market in South Africa, 2016
  • Figure 216: Drivers of buyer power in the generics market in South Africa, 2016
  • Figure 217: Drivers of supplier power in the generics market in South Africa, 2016
  • Figure 218: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2016
  • Figure 219: Factors influencing the threat of substitutes in the generics market in South Africa, 2016
  • Figure 220: Drivers of degree of rivalry in the generics market in South Africa, 2016
  • Figure 221: South Korea generics market value: $ billion, 2012-16
  • Figure 222: South Korea generics market volume: % of total pharma volume, 2012-16
  • Figure 223: South Korea generics market geography segmentation: % share, by value, 2016
  • Figure 224: South Korea generics market value forecast: $ billion, 2016-21
  • Figure 225: South Korea generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 226: Forces driving competition in the generics market in South Korea, 2016
  • Figure 227: Drivers of buyer power in the generics market in South Korea, 2016
  • Figure 228: Drivers of supplier power in the generics market in South Korea, 2016
  • Figure 229: Factors influencing the likelihood of new entrants in the generics market in South Korea, 2016
  • Figure 230: Factors influencing the threat of substitutes in the generics market in South Korea, 2016
  • Figure 231: Drivers of degree of rivalry in the generics market in South Korea, 2016
  • Figure 232: Spain generics market value: $ billion, 2012-16
  • Figure 233: Spain generics market volume: % of total pharma volume, 2012-16
  • Figure 234: Spain generics market geography segmentation: % share, by value, 2016
  • Figure 235: Spain generics market value forecast: $ billion, 2016-21
  • Figure 236: Spain generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 237: Forces driving competition in the generics market in Spain, 2016
  • Figure 238: Drivers of buyer power in the generics market in Spain, 2016
  • Figure 239: Drivers of supplier power in the generics market in Spain, 2016
  • Figure 240: Factors influencing the likelihood of new entrants in the generics market in Spain, 2016
  • Figure 241: Factors influencing the threat of substitutes in the generics market in Spain, 2016
  • Figure 242: Drivers of degree of rivalry in the generics market in Spain, 2016
  • Figure 243: Turkey generics market value: $ billion, 2012-16
  • Figure 244: Turkey generics market volume: % of total pharma volume, 2012-16
  • Figure 245: Turkey generics market geography segmentation: % share, by value, 2016
  • Figure 246: Turkey generics market value forecast: $ billion, 2016-21
  • Figure 247: Turkey generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 248: Forces driving competition in the generics market in Turkey, 2016
  • Figure 249: Drivers of buyer power in the generics market in Turkey, 2016
  • Figure 250: Drivers of supplier power in the generics market in Turkey, 2016
  • Figure 251: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2016
  • Figure 252: Factors influencing the threat of substitutes in the generics market in Turkey, 2016
  • Figure 253: Drivers of degree of rivalry in the generics market in Turkey, 2016
  • Figure 254: United Kingdom generics market value: $ billion, 2012-16
  • Figure 255: United Kingdom generics market volume: % of total pharma volume, 2012-16
  • Figure 256: United Kingdom generics market geography segmentation: % share, by value, 2016
  • Figure 257: United Kingdom generics market value forecast: $ billion, 2016-21
  • Figure 258: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 259: Forces driving competition in the generics market in the United Kingdom, 2016
  • Figure 260: Drivers of buyer power in the generics market in the United Kingdom, 2016
  • Figure 261: Drivers of supplier power in the generics market in the United Kingdom, 2016
  • Figure 262: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016
  • Figure 263: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016
  • Figure 264: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016
  • Figure 265: United States generics market value: $ billion, 2012-16
  • Figure 266: United States generics market volume: % of total pharma volume, 2012-16
  • Figure 267: United States generics market geography segmentation: % share, by value, 2016
  • Figure 268: United States generics market value forecast: $ billion, 2016-21
  • Figure 269: United States generics market volume forecast: % of total pharma volume, 2016-21
  • Figure 270: Forces driving competition in the generics market in the United States, 2016
  • Figure 271: Drivers of buyer power in the generics market in the United States, 2016
  • Figure 272: Drivers of supplier power in the generics market in the United States, 2016
  • Figure 273: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016
  • Figure 274: Factors influencing the threat of substitutes in the generics market in the United States, 2016
  • Figure 275: Drivers of degree of rivalry in the generics market in the United States, 2016
  • Figure 276: Allergan plc: revenues & profitability
  • Figure 277: Allergan plc: assets & liabilities
  • Figure 278: Mylan Inc.: revenues & profitability
  • Figure 279: Mylan Inc.: assets & liabilities
  • Figure 280: Teva Pharmaceutical Industries Limited: revenues & profitability
  • Figure 281: Teva Pharmaceutical Industries Limited: assets & liabilities
  • Figure 282: Sun Pharmaceutical Industries Ltd.: revenues & profitability
  • Figure 283: Sun Pharmaceutical Industries Ltd.: assets & liabilities
  • Figure 284: Sanofi SA: revenues & profitability
  • Figure 285: Sanofi SA: assets & liabilities
  • Figure 286: STADA Arzneimittel AG: revenues & profitability
  • Figure 287: STADA Arzneimittel AG: assets & liabilities
  • Figure 288: Aspen Pharmacare Holdings Ltd: revenues & profitability
  • Figure 289: Aspen Pharmacare Holdings Ltd: assets & liabilities
  • Figure 290: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
  • Figure 291: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
  • Figure 292: Aurobindo Pharma Limited: revenues & profitability
  • Figure 293: Aurobindo Pharma Limited: assets & liabilities
  • Figure 294: Cipla Limited: revenues & profitability
  • Figure 295: Cipla Limited: assets & liabilities
  • Figure 296: Lupin Limited: revenues & profitability
  • Figure 297: Lupin Limited: assets & liabilities
  • Figure 298: PT Kalbe Farma Tbk: revenues & profitability
  • Figure 299: PT Kalbe Farma Tbk: assets & liabilities
  • Figure 300: PT Indofarma (Persero), Tbk: revenues & profitability
  • Figure 301: Daiichi Sankyo Co., Ltd.: revenues & profitability
  • Figure 302: Daiichi Sankyo Co., Ltd.: assets & liabilities
  • Figure 303: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
  • Figure 304: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
  • Figure 305: Abbott Laboratories: revenues & profitability
  • Figure 306: Abbott Laboratories: assets & liabilities
  • Figure 307: Krka, d. d., Novo mesto: revenues & profitability
  • Figure 308: Krka, d. d., Novo mesto: assets & liabilities
  • Figure 309: Adcock Ingram Holdings Limited: revenues & profitability
  • Figure 310: Adcock Ingram Holdings Limited: assets & liabilities
  • Figure 311: Yuhan Corporation: revenues & profitability
  • Figure 312: Yuhan Corporation: assets & liabilities
  • Figure 313: DEVA Holding: revenues & profitability
  • Figure 314: DEVA Holding: assets & liabilities
Back to Top